A Durable Response to Osimertinib in an Elderly Patient With EGFR T790M Positive Metastatic Non-Small-Cell Lung Cancer After Progression on Erlotinib

被引：2
|
作者：
Tariq, Zeeshan [1 ]
Blyly, Mckenna [2 ]
机构：
[1] Bronson Canc Care Ctr, Homer Stryker Sch Med, Battle Creek, MI 49017 USA
[2] Bronson Canc Care Ctr, Battle Creek, MI USA
来源：
AMERICAN JOURNAL OF THERAPEUTICS | 2023年 / 30卷 / 05期
关键词：
D O I：
10.1097/MJT.0000000000001598
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：E463 / E465
页数：3
相关论文
共 50 条
  • [1] The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
    Gao, Xin
    Le, Xiuning
    Costa, Daniel B.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (04) : 383 - 390
  • [2] Differential efficacy of Osimertinib in EGFR T790M positive non-small cell lung cancer by metastatic site
    Uematsu, Shinya
    ANNALS OF ONCOLOGY, 2019, 30 : 109 - 109
  • [3] Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Khozin, Sean
    Weinstock, Chana
    Blumenthal, Gideon M.
    Cheng, Joyce
    He, Kun
    Zhuang, Luning
    Zhao, Hong
    Charlab, Rosane
    Fan, Ingrid
    Keegan, Patricia
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2017, 23 (09) : 2131 - 2135
  • [4] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Hirano, Toshiyuki
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
  • [5] High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer
    Ariyasu, Ryo
    Nishikawa, Shingo
    Uchibori, Ken
    Oh-hara, Tomoko
    Yoshizawa, Takahiro
    Dotsu, Yosuke
    Koyama, Junji
    Saiki, Masafumi
    Sonoda, Tomoaki
    Kitazono, Satoru
    Yanagitani, Noriko
    Horiike, Atsushi
    Inase, Naohiko
    Kasahara, Kazuo
    Nishio, Makoto
    Katayama, Ryohei
    LUNG CANCER, 2018, 117 : 1 - 6
  • [6] Practical use of osimertinib in Japanese patients with EGFR T790M mutation positive advanced non-small-cell lung cancer
    Kotake, M.
    Murakami, H.
    Naito, T.
    Takahashi, T.
    Kenmotsu, H.
    Ono, A.
    Wakuda, K.
    Nakashima, K.
    Omori, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status
    Nakashima, Kazuhisa
    Kimura, Madoka
    Akamatsu, Hiroaki
    Daga, Haruko
    Imai, Hisao
    Taira, Tetsuhiko
    Ko, Ryo
    Hisamatsu, Yasushi
    Nishino, Kazumi
    Sugimoto, Takeya
    Miyashita, Yosuke
    Takahashi, Toshiaki
    Kumagai, Toru
    Yamamoto, Nobuyuki
    Murakami, Haruyasu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (07) : 671 - 675
  • [8] Targeting the EGFR T790M mutation in non-small-cell lung cancer
    Normanno, Nicola
    Maiello, Monica Rosaria
    Chicchinelli, Nicoletta
    Iannaccone, Alessia
    Esposito, Claudia
    De Cecio, Rossella
    D'alessio, Amelia
    De Luca, Antonella
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2017, 21 (02) : 159 - 165
  • [9] Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation
    Imamura, Fumio
    Kimura, Madoka
    Yano, Yukihiro
    Mori, Masahide
    Suzuki, Hidekazu
    Hirashima, Tomonori
    Ihara, Shouichi
    Komuta, Kiyoshi
    Shiroyama, Takayuki
    Nagatomo, Izumi
    Kumagai, Toru
    FUTURE ONCOLOGY, 2020, 16 (21) : 1537 - 1546
  • [10] Mixed Response of Non-Small Cell Lung Cancer Harboring the EGFR T790M Mutation to Osimertinib
    Shinno, Y.
    Goto, Y.
    Sato, J.
    Morita, R.
    Matsumoto, Y.
    Murakami, S.
    Kanda, S.
    Horinouchi, H.
    Fujiwara, Y.
    Yamamoto, N.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2145 - S2145
12345